89Zr-HDL PET示踪剂监测CSF1R抑制剂疗效
研究在MMTV-PyMT小鼠中使用CSF1R抑制剂pexidartinib减少肿瘤相关巨噬细胞(TAM),以89Zr标记的高密度脂蛋白(89Zr-HDL)纳米示踪剂行PET/CT成像。结果显示pexidartinib组肿瘤内89Zr-HDL摄取显著低于对照组(2.9%±0.3% vs 3.7%±0.2% ID/g),并与TAM密度下降相关,提示该示踪剂可用于快速监测靶向TAM的治疗反应。
要点
- 89Zr-HDL PET可无创监测CSF1R抑制剂引起的TAM减少。
- pexidartinib组肿瘤摄取2.9%±0.3% ID/g,低于对照组的3.7%±0.2% ID/g。
- 示踪剂摄取下降与免疫荧光测定的TAM密度降低相关。
核心结论
- 89Zr-HDL纳米颗粒有潜力作为PET示踪剂快速监测CSF1R抑制剂及其他靶向TAM治疗策略的反应。
研究设计与样本
- 雌性MMTV-PyMT小鼠接受CSF1R抑制剂pexidartinib治疗以减少TAM密度,对照接受溶剂。
- 使用PET/CT成像和放射自显影评估肿瘤内89Zr-HDL积聚,免疫荧光测定TAM负荷。
主要发现
- PET/CT图像显示pexidartinib治疗组肿瘤内89Zr-HDL积聚较对照组显著减少。
- pexidartinib组和对照组每克注射剂量百分比分别为2.9%±0.3%和3.7%±0.2%。
- 离体结果证实该减少,并与TAM密度下降相关。
临床怎么用
- 89Zr-HDL PET有望用于早期评估靶向TAM的免疫治疗是否起效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The immune function within the tumor microenvironment has become a prominent therapeutic target, with tumor-associated macrophages (TAMs) playing a critical role in immune suppression. We propose an 89Zr-labeled high-density lipoprotein (89Zr-HDL) nanotracer as a means of monitoring response to immunotherapy. Methods: Female MMTV-PyMT mice were treated with pexidartinib, a colony-stimulating factor 1 receptor (CSF1R) inhibitor, to reduce TAM density. The accumulation of 89Zr-HDL within the tumor was assessed using PET/CT imaging and autoradiography, whereas TAM burden was determined using immunofluorescence. Results: A significant reduction in 89Zr-HDL accumulation was observed in PET/CT images, with 2.9% ± 0.3% and 3.7% ± 0.2% injected dose/g for the pexidartinib- and vehicle-treated mice, respectively. This reduction was corroborated ex vivo and correlated with decreased TAM density. Conclusion: These results support the potential use of 89Zr-HDL nanoparticles as a PET tracer to quickly monitor the response to CSF1R inhibitors and other therapeutic strategies targeting TAMs.
引用
- Mason CA, Kossatz S, Carter LM, et al. An 89Zr-HDL PET Tracer Monitors Response to a CSF1R Inhibitor. J Nucl Med. 2019. PMID: 31420495. doi:10.2967/jnumed.119.230466
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。